FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Guide on Generic User Fee Assessments

Federal Register notice: FDA makes available a final guidance entitled Assessing User Fees Under the Generic Drug User Fee Amendments of 2017.

Human Drugs

Senate Bill to Restore FDA Orphan Drug Interpretation

Senators Tammy Baldwin (D-WI) and Bill Cassidy (R-LA) introduce legislation entitled the Retaining Access and Restoring Exclusivity (RARE) Act, which ...

FDA General

Senate Draft User Fee Bill Sets IVD Regulation

The Senate HELP Committee releases a discussion draft of a bill that would reauthorize user fee programs for another five years and enhance certain ot...

Human Drugs

Travere Therapeutics NDA Accepted for Sparsentan

FDA accepts for priority review a Travere Therapeutics NDA for sparsentan and its use in treating IgA nephropathy.

Federal Register

Howard Head Debarred for 5 Years

Federal Register notice: FDA debars for five years Howard Stanley Head from importing or offering for import any drug into the U.S.

Human Drugs

Final Guide on Investigating Out-of-spec Results

FDA posts a final guidance entitled Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production.

Medical Devices

Avanos Recalls Cortrak 2 Enteral Access Device

Avanos Medical recalls (Class 1) its Cortrak 2 Enteral Access System due to reports of injuries and patient deaths after nasoenteric or nasogastric tu...

Medical Devices

New Home Covid Test Gives Results for Flu, RSV too

FDA issues an Emergency Use Authorization (EUA) for the Labcorps Covid-19+Flu+RSV Test Home Collection Kit for use with the Labcorp Seasonal Respirato...

Human Drugs

Clinical Hold Lifted on Gilead HIV Therapy

FDA removes a clinical hold on Gilead Sciences injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis.

Human Drugs

FDA Hits Lupins Novel Labs with 13-item 483

A March FDA inspection of Novel Laboratories (dba Lupin Somerset) leads to a 13-item FDA Form-483 that cites significant and repeat GMP deficiencies.